ferric maltol
Trade name: Accrufer
Approved
Jul 25, 2019
Ferric maltol, sold under the brand name Feraccru among others, is an iron containing medication for the treatment of adults with low iron stores. It is taken by mouth. — Wikipedia
Clinical trial activity
12 trials · 11 clinical orgs · 1 marketing orgs
Earliest trial started Aug 1, 2011 (NCT01340872)
Timeline
2010s
- Jan 1, 2011
Shield Therapeutics — Earliest Phase 3 Sponsor(trial)
- Jan 1, 2017
Shield Therapeutics — Earliest Phase 1 Sponsor(trial)
- Jul 25, 2019
Shield Therapeutics — Earliest FDA Approval
- Jul 25, 2019
Shield Therapeutics — Marketing Organization
- Jul 25, 2019
Shield Therapeutics — NDA Organization
Indications
Approved for
Mechanism of action
- Transferrin receptorBINDING AGENT
Transferrin receptor binding agent
- Unspecified targetOTHER
Supplement
Iron replacement product that delivers iron for intestinal uptake which is then transferred to ferritin and transferrin.
Approval history
- approvedJul 25, 2019
Chemistry & pharmacology
- Mol. weight
- 431.15 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaFerric maltol ↗
- ChEMBLCHEMBL4298110 ↗
Also known as
- feraccru
- ferric maltol
- ferric maltol
- ferric maltol
- ferric maltol
- ferric maltol
- iron (iii) maltol
- st10-021
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05697211 | Phase 4 | Feb 21, 2023 | Gottfried Wilhelm Leibniz Universität Hannover, Norgine |
| NCT05456932 | Phase 4 | Aug 19, 2022 | Leiden University, Maastricht University, Radboud University, University of Groningen |
| NCT05177484 | Phase 3 | May 30, 2022 | Norgine, The Royal Wolverhampton NHS Trust |
| NCT05126901 | Phase 3 | Oct 4, 2021 | Shield Therapeutics |
| NCT04626414 | Phase 1 | Sep 28, 2020 | Shield Therapeutics |
| NCT03774615 | Phase 4 | Mar 18, 2019 | Gottfried Wilhelm Leibniz Universität Hannover, Shields, Shields and Associates |
| NCT03371173 | Phase 3 | Mar 27, 2018 | Gottfried Wilhelm Leibniz Universität Hannover, Hannover Clinical Trial Center GmbH, Shields, Shields and Associates |
| NCT03181451 | Phase 1 | Mar 14, 2017 | Medpace, Inc., Shield Therapeutics |
| NCT02968368 | Phase 3 | Nov 1, 2016 | Shield Therapeutics |
| NCT02680756 | Phase 3 | Jan 1, 2016 | Shield Therapeutics |
| NCT01340872 | Phase 3 | Aug 1, 2011 | Shield Therapeutics |
| NCT01352221 | Phase 3 | Aug 1, 2011 | Shield Therapeutics |
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shield Therapeutics | For profit | 7 | 7 | 2 | 2011 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 3 | 3 | 2 | 2018 |
| Norgine | For profit | 2 | 0 | 2 | 2022 |
| Shields, Shields and Associates | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Hannover Clinical Trial Center GmbH | For profit | 1 | 0 | 1 | 2018 |
| Leiden University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Maastricht University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2017 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| The Royal Wolverhampton NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2022 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Shield Therapeutics | For profit | MKTG | Jul 25, 2019 |
| Shield Therapeutics | For profit | NDA | Jul 25, 2019 |